Feuvret L, Antoni D, Biau J, Truc G, Noël G, Mazeron J-J
Service de radiothérapie, CHU Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
Département universitaire de radiothérapie, centre Paul-Strauss, Unicancer, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg, France.
Cancer Radiother. 2016 Sep;20 Suppl:S69-79. doi: 10.1016/j.canrad.2016.07.008. Epub 2016 Aug 9.
Gliomas are the most frequent primary brain tumours. Treating these tumours is difficult because of the proximity of organs at risk, infiltrating nature, and radioresistance. Clinical prognostic factors such as age, Karnofsky performance status, tumour location, and treatments such as surgery, radiation therapy, and chemotherapy have long been recognized in the management of patients with gliomas. Molecular biomarkers are increasingly evolving as additional factors that facilitate diagnosis and therapeutic decision-making. These practice guidelines aim at helping in choosing the best treatment, in particular radiation therapy.
胶质瘤是最常见的原发性脑肿瘤。由于存在风险的器官位置临近、浸润性生长特性以及放射抗性,治疗这些肿瘤颇具难度。临床预后因素,如年龄、卡氏功能状态、肿瘤位置,以及手术、放射治疗和化疗等治疗方法,长期以来在胶质瘤患者的管理中已得到认可。分子生物标志物正日益成为有助于诊断和治疗决策的额外因素。这些实践指南旨在帮助选择最佳治疗方法,尤其是放射治疗。